Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, the investigators aimed to observe the effects of medium cut-off dialysis filters and high-flux dialysis filters on malnutrition inflammation score, uremic itching, restless leg syndrome, anemia, and ESA treatment, which are prominent complications in hemodialysis, and routine follow-up parameters.
The study is designed as a single-center, prospective, observational research. A total of 50 stable-course chronic hemodialysis patients over 18 years of age and treated for at least 3 months will be included in the study and the study period will be planned for 12 months. 25 of the 50 chronic hemodialysis patients planned to be included in the study will use MCO-membrane and the other 25 will use high-flux membrane. The distribution of patients to the high-flux membrane and MCO membrane groups will be done randomly (sequentially single-pair number method). Then, the standard 12-hour (3x4 hours/week) hemodialysis treatment will continue. At the beginning of the study (0.), at the end of the third (3.) month and at the end of the sixth (6.) month;
Monthly laboratory tests routinely performed on hemodialysis patients (tests routinely performed in hemodialysis patient follow-up) 5 ml blood samples will be taken from the hemodialysis set to determine the levels of medium-large molecule-weight toxins-wastes and inflammatory parameters before and after dialysis, and the sera will be separated and stored at -80oC for use at the end of the study.
Automatic blood pressure measurement will be performed before and after hemodialysis to evaluate arterial stiffness.
The Malnutrition Inflammation Score will be applied to evaluate the nutritional status (the MIS form is given in the appendix) Visual Analog Scale will be used for appetite Visual Analog Scale will be used for uremic pruritus Depression scale screening (Beck's scale)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| The Theranova 400 group, also known as the MCO group. | Patients undergoing maintenance hemodialysis will receive dialysis treatment using the Theranova 400 device. |
| |
| The FX80 group, also known as the high-flux group. | Patients undergoing maintenance hemodialysis will receive dialysis treatment using the FX80 device. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dialysis using the Theranova-400 device. | Device | Patients receive hemodialysis treatment using the Theranova-400 dialyzer. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Malnutrition-inflammation score (MIS) | At the start of the study, the malnutrition-inflammation score will be recorded. This score ranges from 0 to 30, with higher scores indicating worse outcomes. | Prior to randomization, at the start of the study. |
| Malnutrition-inflammation score (MIS) | The malnutrition-inflammation score will be recorded at the conclusion of the study. This score ranges from 0 to 30, with higher scores indicating worse outcomes. | At the end of the 6th month after randomization. |
| Depressive disorder | At the start of the study, the Beck's depression scale will be recorded. This score ranges from 0 to 63, with higher scores indicating worse depression. | Prior to randomization, at the start of the study. |
| Depressive disorder | At the conclusion of the study, the Beck's depression scale will be recorded. This score ranges from 0 to 63, with higher scores indicating worse depression. | At the end of the 6th month after randomization. |
| Uremic pruritus | At the start of the study, the visual analog scale for pruritus will be recorded. This score ranges from 0 to 10, with higher scores indicating worse itching. | Prior to randomization, at the start of the study. |
| Uremic pruritus | At the conclusion of the study, the visual analog scale for pruritus will be recorded. This score ranges from 0 to 10, with higher scores indicating worse itching. | At the end of the 6th month after randomization. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Prevalent patients who are receiving hemodialysis treatment three times a week and are otherwise in stable condition.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tuncay Sahutoglu, M.D. | Mehmet Akif Inan Training and Research Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mehmet Akif Inan Training and Research Hospital | Sanliurfa | Karaköprü | 63000 | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Serum and plasma extracts from venous blood samples were stored at -80C of the hospital.
| Dialysis using the FX80 device. | Device | Patients receive hemodialysis treatment using the FX80 dialyzer. |
|
| Restless leg syndrome | At the start of the study, the Restless Leg Syndrome screening questionnaire will be administered. This score ranges from 0 to 40, with higher scores indicating worse symptoms. | Prior to randomization, at the start of the study. |
| Restless leg syndrome | At the conclusion of the study, the Restless Leg Syndrome screening questionnaire will be administered. This score ranges from 0 to 40, with higher scores indicating worse symptoms. | At the end of the 6th month after randomization. |
| Appetite | At the start of the study, the visual analog scale of appetite will be recorded. This score ranges from 0 to 5, with higher scores indicating better appetite. | Prior to randomization, at the start of the study. |
| Appetite | At the conclusion of the study, the visual analog scale of appetite will be recorded. This score ranges from 0 to 5, with higher scores indicating better appetite. | At the end of the 6th month after randomization. |
| Hemoglobin | Hemoglobin levels will be measured on a monthly basis. | March 2020 |
| Hemoglobin | Hemoglobin levels will be measured on a monthly basis. | April 2020 |
| Hemoglobin | Hemoglobin levels will be measured on a monthly basis. | May 2020 |
| Hemoglobin | Hemoglobin levels will be measured on a monthly basis. | June 2020 |
| Hemoglobin | Hemoglobin levels will be measured on a monthly basis. | July 2020 |
| Hemoglobin | Hemoglobin levels will be measured on a monthly basis. | August 2020 |
| Hemoglobin | Hemoglobin levels will be measured on a monthly basis. | September 2020 |
| Erythropoietin Doses | Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis. | March 2020 |
| Erythropoietin Doses | Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis. | April 2020 |
| Erythropoietin Doses | Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis. | May 2020 |
| Erythropoietin Doses | Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis. | June 2020 |
| Erythropoietin Doses | Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis. | July 2020 |
| Erythropoietin Doses | Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis. | August 2020 |
| Erythropoietin Doses | Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis. | September 2020 |
| Phosphorus levels control | Serum phosphorus levels will be tested on a monthly basis. | March 2020 |
| Phosphorus levels control | Serum phosphorus levels will be tested on a monthly basis. | April 2020 |
| Phosphorus levels control | Serum phosphorus levels will be tested on a monthly basis. | May 2020 |
| Phosphorus levels control | Serum phosphorus levels will be tested on a monthly basis. | June 2020 |
| Phosphorus levels control | Serum phosphorus levels will be tested on a monthly basis. | July 2020 |
| Phosphorus levels control | Serum phosphorus levels will be tested on a monthly basis. | August 2020 |
| Phosphorus levels control | Serum phosphorus levels will be tested on a monthly basis. | September 2020 |
| Parathyroid hormone levels control | Serum parathyroid hormone levels will be tested on a monthly basis. | March 2020 |
| Parathyroid hormone levels control | Serum parathyroid hormone levels will be tested on a monthly basis. | April 2020 |
| Parathyroid hormone levels control | Serum parathyroid hormone levels will be tested on a monthly basis. | May 2020 |
| Parathyroid hormone levels control | Serum parathyroid hormone levels will be tested on a monthly basis. | June 2020 |
| Parathyroid hormone levels control | Serum parathyroid hormone levels will be tested on a monthly basis. | July 2020 |
| Parathyroid hormone levels control | Serum parathyroid hormone levels will be tested on a monthly basis. | August 2020 |
| Parathyroid hormone levels control | Serum parathyroid hormone levels will be tested on a monthly basis. | September 2020 |
| ID | Term |
|---|---|
| D012148 | Restless Legs Syndrome |
| D003866 | Depressive Disorder |
| ID | Term |
|---|---|
| D009422 | Nervous System Diseases |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D020447 | Parasomnias |
| D001523 | Mental Disorders |
| D019964 | Mood Disorders |
Not provided
Not provided